ProCE Banner Activity

My Thoughts on Adjuvant Targeted Therapy for BRAF V600E/K, High-Risk, Resected Melanoma

Clinical Thought
How do you choose among approved adjuvant therapies for BRAF V600E/K high-risk melanoma? Read my thoughts on factors to consider when selecting adjuvant targeted therapy for your patients.

Released: October 19, 2020

Expiration: October 18, 2021

Share

Faculty

Douglas T. Dieterich

Douglas T. Dieterich, MD

Professor of Medicine
Division of Liver Diseases
Director, Continuing Medical Education
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Douglas Jacoby

Douglas Jacoby, MD

Associate Professor of Clinical Medicine
University of Pennsylvania Health System
Director
Penn Cardiology Preventive Care
Medical Director
Penn Presbyterian Heart and Vascular Pavilion
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Douglas T. Dieterich, MD

Professor of Medicine
Division of Liver Diseases
Director, Continuing Medical Education
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Douglas B. Johnson, MD, MSCI, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Catalyst, Iovance, Merck, and Novartis and funds for research support from Bristol-Myers Squibb.

Douglas Jacoby, MD

Associate Professor of Clinical Medicine
University of Pennsylvania Health System
Director
Penn Cardiology Preventive Care
Medical Director
Penn Presbyterian Heart and Vascular Pavilion
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Douglas B. Johnson, MD, MSCI, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Catalyst, Iovance, Merck, and Novartis and funds for research support from Bristol-Myers Squibb.